We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01241786
Recruitment Status : Terminated (anticipated results not seen and population not seen)
First Posted : November 16, 2010
Last Update Posted : November 8, 2012
Celgene Corporation
Information provided by (Responsible Party):
Hackensack University Medical Center

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Primary Completion Date : October 2011
  Study Completion Date : October 2011

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 21, 2013 July 9, 2013
2 July 17, 2013  
3 July 30, 2013 August 30, 2013
4 September 3, 2013  
5 September 12, 2013  
6 September 13, 2013  
7 September 20, 2013 November 21, 2013
8 November 25, 2013  
9 December 3, 2013  
10 December 20, 2013  
11 February 28, 2014 April 11, 2014